![[Trade Alert] Provention Bio (PRVB) Drops The F Bomb](https://disruptivetr.com/wp-content/uploads/2020/06/PRVB.F.Bomb_.jpg)
[Trade Alert] Provention Bio (PRVB) Drops The F Bomb
Provention Bio (PRVB) announced an offering after the bell yesterday on the heel’s of new data for its Type 1 Diabetes treatment. Here’s what I recommend…
CUE: The Data’s In… Kind Of
Cue Biopharma (CUE) released preliminary Phase 1A data this morning. There are several incremental updates. Here are the key takeways…
ICYMI – Week of June 1, 2020
Russell 2000 Index annual rebalance list to be announced this week and likely includes three of our active recommendations.
CUE: Here Comes The Data?
Cue Biopharma (CUE) is set to present interim Phase 1 data for CUE-101, which could start a rally that ulimately sees shares rise to $150. Here’s why…
CUE Q1 Preview: Data Release And Share Surge Imminent?
Cue Biopharma (CUE) is set to report Q1 2020 results. Here are six reasons why I expect positive data to come imminently and why shares could rally to $150+
ATOM: Cashed Up And Ready To Rally To $25+
Atomera Inc. (ATOM) surprised the market with an equity offering, but it’s not an indication that commercial news if now delayed. Here’s why…
ATOM Q1 Preview: Patiently Waiting For Blast Off To $25
Atomera Inc. (ATOM) is set to report Q1 2020 results. Here’s why a single announcement could propel shares 3X to 5X higher than current prices…
CUE: Why Shares Could Be Worth $150 Or More
Shares of Cue Biopharma (CUE) are up more than 100% from our entry. But I’m letting this winner ride, as four relevant biotech deals point to another 97% to 637% upside to current prices. Here are all the details…
DTR: Q1 Portfolio Review & 2020 Tech Trend Outook
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
PRVB: Major Risks Retired, Major Upside Ahead
Shares of Provention Bio (PRVB) have staged an impressive rally since announcing game-changing data on teplizumab for the treatment of patients at-risk of developing Type 1 Diabetes. But there’s plenty more upside ahead. Here’s why…